Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Explore this paper's citation graph
Summary
This work demonstrates that PI3K has increased enzymatic activity and that PI3K-δ is expressed in CLL cells, and provides rationale for the clinical development of CAL-101 as a first-in-class targeted therapy for CLL and related B-cell lymphoproliferative disorders.
- Type
- article
- Published
- 2010-09-23
- Cited by
- 568
- References
- 57
- Access
- Open access
- OpenAlex
- https://openalex.org/W2025786205
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:29321261
Keywords
Chronic lymphocytic leukemia, Cancer research, PI3K/AKT/mTOR pathway, Imatinib, Immunology
References
- The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
- Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation.
- National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
- Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia.
- Cutting Edge: The Phosphoinositide 3-Kinase p110δ Is Critical for the Function of CD4+CD25+Foxp3+ Regulatory T Cells1
- Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.
- The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
- Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies.
- Phosphoinositide 3-kinase signalling pathways.
- The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
- Triterpenoids Display Single Agent Anti-tumor Activity in a Transgenic Mouse Model of Chronic Lymphocytic Leukemia and Small B Cell Lymphoma
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- P110delta, a novel phosphoinositide 3-kinase in leukocytes.
- Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.
- Novel immune-based treatment strategies for chronic lymphocytic leukemia.
- PI3 Kinase signals BCR dependent mature B cell survival
- Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells
- Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase
- Immune deposit nephritis and single-component cryoglobulinemia associated with chronic lymphocytic leukemia. Evidence for a role of circulating IgG-anti-IgG immune complexes in the pathogenesis of the renal lesion.
- Signalling by PI3K isoforms: insights from gene-targeted mice.
Cited by
- Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future.
- Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation
- Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms
- The CLL cell microenvironment.
- Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches.
- Rewiring of sIgM-Mediated Intracellular Signaling through the CD180 Toll-like Receptor
- Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia
- INVESTIGATING APOPTOSIS PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA: STROMAL INFLUENCE AND THERAPEUTIC ACTIVATION
- Biology of Chronic Lymphocytic Leukemia in Different Microenvironments: Clinical and Therapeutic Implications
- PI3Ks-drug targets in inflammation and cancer.
- CD180/RP105 Toll-like Receptor (TLR) mediated signalling in Chronic Lymphocytic Leukaemia
- The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.
- Передача сигнала через B-клеточный рецептор: механизмы и ингибиторы
- Differential splicing of oncogenes and tumor suppressor genes in African and Caucasian American populations: contributing factor in prostate cancer disparities
- Stem Cell Transplantation
- A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo
- Identification of LCK as a key mediator of B cell receptor (BCR)signalling in chronic lymphocytic leukaemia (CLL)
- B-cell receptor signaling in the pathogenesis of lymphoid malignancies.
- B lymphoid malignancies: insights from mouse models
- Recent Advances in the Pathogenesis and Treatment of Chronic Lymphocytic Leukemia
Related papers
- Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase.
- Expression and significance of Axl in chronic myeloid leukemia treated with imatinib
- Monitoring imatinib plasma concentrations in chronic myeloid leukemia
- Chronic myeloid leukemia in the imatinib era
- PCN69 COST-EFFECTIVENESS ANALYSIS OF DASATINIB 100 MG VS. IMATINIB 800 MG IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN
- Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
- Current status of imatinib as frontline therapy for chronic myeloid leukemia.
- Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up